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Abstract
Background: Milroy-like disease is the diagnostic definition used for patients with 
phenotypes that resemble classic Milroy disease (MD) but are negative to genetic 
testing for FLT4. In this study, we aimed at performing a genetic characterization 
and biochemical analysis of VEGF-C variations found in a female proband born with 
congenital edema consistent with Milroy-like disease.
Methods: The proband underwent next-generation sequencing-based genetic test-
ing for a panel of genes associated with known forms of hereditary lymphedema. 
Segregation analysis was performed on family members by direct sequencing. In 
vitro studies were performed to evaluate the role of a novel identified variant.
Results: Two VEGF-C variations were found in the proband, a novel p.(Ser65Arg) 
and a pathogenic c.148-3_148-2delCA, of paternal and maternal origin, respectively. 
Functional characterization of the p.(Ser65Arg) variation in vitro showed alterations 
in VEGF-C processing.
Conclusions: Our findings reveal an interesting case in which biallelic variants in 
VEGF-C are found in a patient with Milroy-like lymphedema. These data expand our 
understanding of the etiology of congenital Milroy-like lymphedema.
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1 |  INTRODUCTION
Lymphedema comprises a series of conditions character-
ized by impaired lymph transport, leading to lymph stagna-
tion in the interstitium, especially in subcutaneous tissues 
(Rockson, 2006). Fluid accumulation in tissues can manifest 
as swelling in specific parts of the body, mainly in the lower 
limbs, but also in the upper limbs, face, and genitals. Primary 
lymphedema is the term used when the lymphedema is not 
caused by another medical condition. Milroy disease (MD) 
is a congenital form of lymphedema with autosomal domi-
nant inheritance, characterized by painless unilateral edema, 
often present at birth, usually affecting the dorsum of the feet 
and extending to the lower limb. In about 70% of cases, MD 
is associated with missense point mutations of the FMS-like 
tyrosine kinase 4 gene, FLT4 (MIM 136352), which encodes 
the vascular endothelial growth factor receptor 3 (VEGFR-3) 
(Connell et al., 2009). Recent studies have shown that vari-
ants in VEGF-C (MIM 601528), the gene coding for one of 
the VEGFR-3 ligands, can lead to a MD-like phenotype; five 
families with dominantly inherited lymphedema have been 
so far described to present heterozygous VEGF-C variants 
(Balboa-Beltran et  al.,  2014; Fastré et  al.,  2018; Gordon 
et al., 2013b; Nadarajah et al., 2018).
VEGF-C, important for lymph vessel development, is 
synthesized as precursor protein, which undergoes proteo-
lytic processing which increases its affinity for its receptors, 
VEGFR-2 and VEGFR-3, with the consequent activation of in-
tracellular signaling involved in lymphangiogenesis (Alitalo, 
Tammela, & Petrova, 2005; Tammela & Alitalo, 2010). The 
metalloproteinase ADAMTS3 has been shown to directly 
interact with VEGF-C and induce its proteolytic process-
ing. However, the processing of VEGF-C by ADAMTS3 
is enhanced by the collagen and calcium-binding EGF do-
main-containing protein 1 (CCBE1) (Bui et al., 2016).
Here, we report an interesting family case of a patient 
with a disease resembling MD that, by a sequencing anal-
ysis, showed biallelic variants in VEGF-C. To clarify the 
role of these variants, further investigations were carried out. 
Clinical examination of the family by lymphoscintigraphy as 
well as biochemical in vitro assays is supportive for a role of 
both variants in the development of the proband phenotype. 
Our experiments demonstrate that proteolytic processing of 
the novel VEGF-C Ser65Arg variant is decreased compared 
to wild-type VEGF-C. These data expand our understanding 
of the etiology of congenital Milroy-like lymphedema.
2 |  METHODS
All studies on human subjects were performed according to 
the Declaration of Helsinki rules and after approval of the 
Ethical Committee of the San Raffaele Hospital.
2.1 | Lymphoscintigraphic assessment
All clinical diagnostics and tests were performed 
at the Department of Radiology of Cuneo hospital. 
Lymphoscintigraphic examination was based on 99mTc-albu-
min nanocolloid (NANOCOLL*0.5 Mg Kit, GE Healthcare 
S.r.l.), injected into the interdigital space in both feet. The 
dosing was: 41 + 41 MBq in the proband, 60 + 60 MBq in 
the father, 55 + 5 MBq in the mother, 60 + 60 MBq in the 
elder brother, and 40 + 40 MBq in the proband's twin brother. 
The lymphoscintigrams were recorded in three phases ac-
cording to the protocol of Bourgeois et al. (Bourgeois, Leduc, 
Belgrado, & Leduc, 2009). Briefly, in phases 0–3, the images 
were acquired at the points of injection to verify tracer clear-
ance; in phase 1, the inguinal regions were evaluated at rest 
and a whole-body scan of ninety 20-s frames was acquired 
in 30 min; phase 2 consisted of dynamic scans centered on 
the groins and whole-body scan during moderate exercise 
(tip-toeing movement of feet and toes); phase 3 consisted of 
whole-body scan after 1 hr of walking or 30 min of stationary 
cycling. Lymphoscintigraphic images obtained from phases 
1 and 3 were analyzed offline by using the automatic area 
plugin of ImageJ software (NIH, http://rsb.info.nih.gov/ij/) to 
determine, in the frontal projection, the distribution area of 
the 99mTc-albumin nanocolloid within lymphatic structures.
2.2 | Sequencing
The genetic diagnosis was done in MAGI’s Lab. All subjects 
received genetic counseling to explain the risks and benefits 
of genetic testing and they signed a consent to make their 
clinical and genetic data available for research purposes. 
DNA was extracted using the Blood DNA kit E.N.Z.A. 
(Omega bio-tek) from blood samples of the proband and 
her four relatives. Genetic profile of the proband was ob-
tained using the next generation sequencing (NGS) approach 
and a panel designed to include the main genes involved 
in primary lymphedema (including MD, Emberger syn-
drome, lymphedema-distichiasis, and other syndromes). 
The coding and adjacent intron regions of the CCBE1 (MIM 
235510; NM_133459), FLT4 (MIM 153100; NM_182925, 
NM_002020), FOXC2 (MIM 153400; NM_005251), 
GATA2 (MIM 614038; NM_001145661), GJC2 (MIM 
613480; NM_020435), SOX18 (MIM 607823; NM_018419), 
VEGF-C (MIM 615907; NM_005429), KIF11 (MIM 
152950; NM_004523), HGF (MIM 142409; NM_000601, 
NM_001010934, NM_001010931), and MET [11] (MIM 
164860; NM_000245, NM_001127500, NM_001324401) 
were analyzed using Nextera Rapid Custom Capture 
Enrichment (Illumina) and NGS on Illumina MiSeq plat-
form (150 bp paired-end reads). To exclude polymorphisms, 
we also searched the public database of single nucleotide 
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variants (dbSNP; www.ncbi.nlm.nih.gov/SNP). To assess 
the pathogenicity of new nucleotide alterations involving 
a change of amino acid residues, we used the PolyPhen 2 
algorithm (Polymorphism Phenotyping v2; http://genet ics.
bwh.harva rd.edu/pph2) with the HumVar-trained model, the 
SIFT algorithm (Sorting Intolerant From Tolerant; http://sift.
bii.a-star.edu.sg) (Kumar, Henikoff, & Ng,  2009), and the 
Variation Taster online predictive tool (http://www.mutat 
ionta ster.org) (Desmet et  al.,  2009). Splicing defects were 
evaluated using the Human Splicing Finder online software 
version 3 (http://www.umd.be/HSF3/HSF.html) [14]. The 
laboratory methods used for genotyping, the bioinformat-
ics pipeline, variants prioritization, and Sanger validation of 
potential pathogenic variants selected have previously been 
described (Manara et al., 2019) and they follow the criteria 
of the American College of Medical Genetics and Genomics 
(ACMG) Standards and Guidelines (Richards et al., 2015). 
Segregation of variants with possible clinical significance 
was performed in family members by direct sequencing.
2.3 | Immunoprecipitation, processing, and 
activity assay
293T cells were transfected with plasmid expression vec-
tors encoding V5-tagged human ADAMTS3 (ADAMTS3-
V5-H6) (Jeltsch et al., 2014) and empty vectors. Conditioned 
media were immunoprecipitated with VEGF-C-NT/Fc (Jha 
et  al.,  2017) or VEGFR-1/Fc (Mäkinen et  al.,  2001) using 
protein A sepharose (PAS, GE Healthcare). The precipi-
tated proteins were subjected to SDS-PAGE, transferred to 
PVDF membrane, followed by ECL detection with anti-V5 
antibody (Invitrogen, #46-0705, 1:6000). The Ser65Arg 
VEGF-C mutant was generated by amplifying the coding 
sequence of full length human VEGF-C (hVEGF-C) in a 
pCDNA3.1-zeo vector according to the QuikChange II XL 
Site-Directed Mutagenesis protocol (Stratagene), using the 
primer pair 5′-gttacggtctgtgtccagggtagatgaactcatgact-3′ and 
5′-agtcatgagttcatctaccctggacacagaccgtaac-3′. The resulting 
mutant construct was sequenced to confirm the presence of 
the mutation using the primers 5′-tccggactcgacctctcgg-3’ and 
5’-ctcttctgtccttgagttgagg-3′.
For the co-immunoprecipitation of VEGF-C with 
ADAMTS3, 293T cells were transfected with DNA ex-
pression vectors encoding for wild-type human VEGF-C 
(VEGF-C-WT), mutant human VEGF-C (VEGF-C-MUT), 
ADAMTS3-V5-H6 (Jeltsch et  al.,  2014) StrepIII-tagged 
human CCBE1 (CCBE1-StrIII (Jeltsch et  al.,  2014), and 
empty vector. After 48 hr, the supernatants were harvested 
and mixed. After 36  hr at 4°C, immunoprecipitation was 
performed with anti-VEGF-C antiserum (Jha et  al.,  2017) 
for 24 hr at 4°C. After washing, the samples were boiled in 
reducing Laemmli buffer and resolved in 10% SDS-PAGE 
gels (for ADAMTS3 detection) or 4%–20% gradient gels (for 
VEGF-C detection) followed by transfer to PVDF membrane 
and detection with anti-ADAMTS3 antibody (Santa Cruz, sc-
21486, 1:700) or with anti-VEGF-C antibody (Santa Cruz, sc-
374628, 1:500). To assess VEGF-C processing and activity, 
293T cells were transfected with expression vectors encoding 
for CCBE1-StrIII (Jha et  al.,  2017) VEGF-C-WT, VEGF-
C-MUT, ADAMTS3-V5-H6 (Jeltsch et  al.,  2014), or empty 
vector. For metabolic labeling experiments, the medium was 
changed after 24 hr to labeling medium (8 μl [35S]cysteine/
[35S]methionine EasyTag label/ml medium; PerkinElmer). 
After 48 hr of labeling, the supernatants were harvested and 
mixed. The mixtures were immunoprecipitated with VEGFR-
3(D1-7)/Fc fusion protein and resolved in a 4%–20% gradi-
ent gel. The dried gel was analyzed by phosphoimaging, and 
scanned using a Typhoon FLA 7000 (GE Healthcare).
2.4 | Statistical analysis
The intensity of Western blot bands was quantified using the 
ImageJ software, analyzed using GraphPad Prism statistical 
analysis software (Version 7), and presented as means ± SD. 
The comparison of two means was performed using unpaired 
Student's t test, and considered significant at p < .05.
3 |  RESULTS
The proband, a 10 years old female, was discovered as the 
only subject with clinical manifestations of Milroy-like 
lymphedema of the right lower limb in a family with living 
parents and two apparently healthy brothers. The family his-
tory was negative for other diseases, and there were no cases 
of lymphatic pathology impairment in the genealogical tree. 
Medical history included natural birth at term of heterozy-
gous twins. Neonatal jaundice and fluctuating swelling of the 
right lower limb were reported since 4 weeks of age; despite 
constant use of compression garments, the patient presented 
with a painless ingravescent stage 3 lymphedema of the right 
lower limb (Figure 1a), particularly affecting the dorsum of 
the feet and extending to the lower limb, typical for Milroy's 
disease. No varicose veins or signs of lymphangitis were ever 
observed. To better investigate the clinical and genetic profile 
of the disease, clinical and lymphoscintigraphic examination 
was carried out on the proband and all other family members. 
In addition, genetic screening of known lymphedema associ-
ated genes and their segregation in the family was performed.
The diagnosis of lymphedema was confirmed by three-
phase anterior lymphoscintigraphy (Figure 1b and Table 1). 
Phases 0–3 showed a dramatically reduced clearance of 
the tracer from the injection point in the right limb and 
only slight clearance in the left limb. In phase 1, dynamic 
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inguinal scanning did not show any tracer in the right in-
guinal lymph nodes, whereas the tracer reached the left 
inguinal lymph node, suggesting either hypoplastic lym-
phatic ducts and/or aplasia/hypoplasia of the lymph nodes. 
In phase 2, during moderate exercise, the images did not 
show any tracer on the right side, whereas a moderate in-
crease in tracer was evident in the left groin. In phase 3, 
whole-body lymphoscintigrams, recorded after 45 min of 
moderately intense bicycle ergometer exercise followed by 
1  hr of walking, indicated dermal back-flow but no lym-
phatic drainage of the right lower limb. Analysis of the left 
side revealed normal visualization of superficial, deep, and 
inguinal lymph nodes and weak activity in abdominal and 
lumbar lymph nodes.
Lymphoscintigraphy of the proband's twin brother 
(AB966) (Figure  1b) indicated reduced clearance from 
F I G U R E  1  (A). Images of the lower limbs of the 10-year-old proband (AB408) show high degree of swelling at the right limb, particularly 
affecting the dorsum of the feet and the lower limb, clearly demonstrating the presence of lymphedema. (B). Anterior bilateral lymphoscintigraphy 
of the lower limbs of proband (panel 1), her twin brother (panel 2), the older brother (panel 3), the mother (panel 4), and the father (panel 5) 
attained at phase 1 (images a, b, c, d, e) and at phase 3 (images a’, b’, c’, d’, e’), respectively
T A B L E  1  Lymphoscintigraphy results. Results of lymphoscintigraphy analysis and corresponding clinical scores for the right (RL) and left 
(LL) limbs in each member of the investigated family. Based on standard lymphoscintigraphy scores, lower limbs were considered normal (7–11), 
mildly altered (12–17), and much altered (18–27)
ID Family grade Gender Age Lymphoscintigraphy score Lymphatic drainage score Clinical manifestation
AB408 Proband Female 10 RL: 19 RL: severe RL: edematous
LL: 11 LL: normal LL: no edema
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the point of injection bilaterally in phases 0–3. A dynamic 
scan of the groins at rest showed tracer in right and left 
lymph nodes in phase 1 and, in phase 2, a rapid increase 
in lymphatic drainage bilaterally after moderate exercise. 
In phase 3, whole-body scan performed at 45 min after in-
jection showed few inguinal lymph nodes on the right side. 
Dermal back-flow was evident in the medial third of the 
right leg, but was attenuated in the second body scan, after 
1 hr of walking. Hence, in spite of the lack of clinical mani-
festations, the patient showed a bilateral delay in lymphatic 
drainage, which was slight in the right leg and severe in the 
left leg.
Lymphoscintigraphy of the proband's elder brother 
(Figure 1b, AB967) did not reveal any relevant impairment 
of lower limb lymphatic drainage in the three phases of the 
examination. None of the two boys presented hydrocele or 
varicose veins.
Lymphoscintigraphy of the mother (Figure  1b, AB965) 
showed a normal bilateral tracer clearance from the point of 
injection in phases 0–3, right and left inguinal lymph node 
activity in phase 1, progressive bilateral increase in lymph 
drainage during moderate exercise in phase 2, and normal 
visualization of superficial lymphatic circulation and of in-
guinal lymph nodes on both sides in whole-body lympho-
scintigrams (phase 3). Lymphoscintigraphy of the father 
(Figure 1b, AB964) showed bilaterally reduced tracer clear-
ance in phases 0–3, no left or right inguinal lymph node ac-
tivity in phase 1 dynamic scan, and a rapid increase in lymph 
drainage on the right and only a minimal increment on the 
left in phase 2 during moderately intense exercise. Finally, 
the whole-body lymphoscintigram scans in phase 3 showed 
a bilateral delay in lymph drainage, slight on the right and 
moderate on the left.
To investigate the molecular bases of the proband dis-
ease, we performed a NGS-based genetic testing for a panel 
of genes associated with most known forms of Mendelian 
lymphedema. The analysis revealed the presence of two 
heterozygous variations in the VEGF-C: (a) a novel p.(Ser-
65Arg) mutation, never described before and of which no 
frequencies are available in any questioned database and 
(b) c.148-3_148-2delCA (Figure  2b,c) which was recently 
demonstrated as pathogenic (Fastré et al., 2018) since it af-
fects splicing of the VEGF-C mRNA, leading to the skipping 
of exons 2 and 3 with the consequent deletion of 135 of the 
419 amino acids of the protein (Fastré et al., 2018).
In silico prediction software Polyphen2, SIFT, and 
Mutation Taster classified the novel Ser65Arg missense 
variant as “probably damaging,” “deleterious,” and “disease 
causing”, respectively.
The results of the family segregation study performed to 
determine whether the variations were in cis (on the same 
allele) or in trans (on different alleles) configuration re-
vealed that the variants in the proband are biallelic. Indeed, 
the father and the proband's twin brother (both with subclin-
ical signs of lymphedema, Figure 1b,c) are heterozygous for 
p.(Ser65Arg), the mother (no altered phenotype) carries the 
c.148-3_148-2delCA, whereas the older healthy brother did 
not inherit either variation of the VEGF-C from his parents 
(Figure 2a).
With the aim to investigate the role of the novel variant, we 
performed in vitro assays. Since the p.(Ser65Arg) mutation 
is in the N-terminal propeptide of VEGF-C (VEGF-C-NT), 
to exclude the presence of subtle differences in protein activ-
ity between the wild-type and mutant protein, we first ana-
lyzed the interaction between VEGF-C-NT and ADAMTS3 
in an immunoprecipitation assay. Immunoblot analysis re-
vealed a strong interaction between an Fc-tagged version of 
the N-terminal domain of VEGF-C (VEGF-C-NT/Fc) and 
ADAMTS3 (Figure 3a, lane 1). We next speculated that the 
Ser65Arg mutation might influence the binding of VEGF-C 
to ADAMTS3. To test this interaction, we mixed conditioned 
media from 293T cells separately transfected with CCBE1, 
ADAMTS3, and wild-type VEGF-C (VEGF-C-WT) or mutant 
VEGF-C (VEGF-C-MUT), where CCBE1 was used in ratio 
of 1:16 in the final reaction volume. The expression of VEGF-
C-WT and VEGF-C-MUT, CCBE1, and ADAMTS3 in 293T 
cells was confirmed by Western blotting (Figure 4a–c). We 
observed a strong interaction between ADAMTS3 and VEGF-
C-WT while the binding of ADAMTS3 to VEGF-C-MUT was 
clearly reduced (Figure 3b, compare lanes 1 and 3, quantifica-
tion in Figure 3c). Based on our previous studies [17], we rea-
soned that high concentrations of CCBE1 and/or ADAMTS3 
could mask differences in the efficiency of VEGF-C activa-
tion. Assuming that differences would become more apparent 
when CCBE1 and/or ADAMTS3 availability were rate-lim-
iting for VEGF-C activation, we performed the assay by 
mixing different amounts of conditioned media from cells 
transformed separately with expression vectors for CCBE1, 
ADAMTS3, and VEGF-C-WT or VEGF-C-MUT. When using 
a ratio of CCBE1-conditioned to ADAMTS3-conditioned to 
VEGF-C-conditioned media of 1:5:5, we observed a clearer 
reduction in the processing of VEGF-C-MUT (Figure 3d).
4 |  DISCUSSION
In this report, we describe an interesting case of a patient 
affected by Milroy-like disease that is associated with bial-
lelic variants in VEGF-C, a gene that has been previously 
associated to Milroy-like disease consistently with an auto-
somal dominant model of inheritance. The variants so far 
reported in just five different families are predicted to form 
dysfunctional proteins (Balboa-Beltran et  al.,  2014; Fastré 
et al., 2018; Gordon et al., 2013a; Nadarajah et al., 2018) and 
studies in animal models suggest that the disease is caused by 
haploinsufficiency (Gordon et al., 2013b).
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F I G U R E  2  (a) Genetic pedigree illustrating the sequencing results performed in all family members. The genetic analysis identified the 
presence of two heterozygous variants in the VEGF-C (NM_005429.5), c.195T>G, and c.148-3_148-2delCA, that are in a trans configuration in 
the proband (arrow), the only family member that manifests the lymphedema with the most severe phenotype (black). Subclinical manifestations 
are illustrated in grey. (b) Electropherogram of a control (WT) and of the proband revealing the deletion and mutation at base position 148 and 195, 
respectively. (c) Schematic representation of the VEGF-C and protein sequences, and location of the newly discovered gene deletion (c.148-3_148-
2delCA) and mutation (c.195T>G (Ser65Arg))
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Here, the variants identified in the proband are a dele-
tion (c.148-3_148-2delCA) recently described as causative 
of lymphedema by Fastrè et al, although with 50% pen-
etrance (Fastré et  al.,  2018) and a novel c.195T>G vari-
ant, never described before and of which no frequencies 
are available in any questioned database. The deletion was 
inherited from the mother, while the novel variant has been 
transmitted by the father to both the proband and her twin 
brother.
In an attempt to disclose the role of the new identified 
variant in the pathogenesis of the disease, we clinically inves-
tigated the actual morphofunctional behavior of the lymphatic 
district of the lower limbs of the family members by perform-
ing individual lymphoscintigraphy. Hence, we may conclude 
that the proband showed a clear bilateral delay of foot-to-in-
guinal region dye distribution, when compared to a normal 
control, thus suggesting an intrinsic defect of the lymphatic 
propulsive machinery at rest. Indeed, normal lymphatics are 
equipped with intraluminal valves between lymphangions 
and with the so-called “anchoring filaments”, macromolec-
ular fibrils that connect the wall of the lymphatic vessels to 
the extracellular macromolecules and the skeletal muscles, 
thus allowing the transmission of forces to the lymphatic wall 
upon tissue displacement and muscle contraction. The lack of 
increment of dye distribution upon exercise in both limbs in 
the proband strongly suggests that these lymphatics not only 
lack their normal intrinsic contractility but are also affected 
by structural-morphological defects or even partial absence 
F I G U R E  3  (a) ADAMTS3 binds to the N-terminal domain of VEGF-C (VEGF-C-NT/Fc). Conditioned media from ADAMTS3-V5-H6 
transfected cells were immunoprecipitated with VEGF-C-NT/Fc fusion protein. ADAMTS3 coprecipitates with VEGF-C-NT/Fc. VEGFR-1/Fc 
was used as control for the Fc part of fusion protein. Notably, a small amount of ADAMTS3 nonspecifically binds to protein A sepharose (PAS, 
lane 2). (b) The Ser65Arg mutation in VEGF-C interferes with ADAMTS3 binding. Conditioned media from CCBE1, ADAMTS3, VEGF-C-WT, 
and VEGF-C-MUT transfected 293T cells were co-incubated with CCBE1 in the ratio of 1:16 and other media at equal amounts for 36 hr at 4°C. 
The mix was then immunoprecipitated with antiserum 6. Compared to VEGF-C-MUT, VEGF-C-WT bound strongly to ADAMTS3-V5-H6 (upper 
panel, lane 1 vs. lane 3). Note that small amounts of ADAMTS3 bind nonspecifically to PAS (upper panel, lane 5). The figure shows two Western 
blots from parallel runs of the same sample. (c) The graph shows densitometric quantification of Western blot band intensity (mean ± SD; n = 3). 
*p < .05. (d) Small amounts of CCBE1 affect processing of the VEGF-C Ser65Arg mutant. Conditioned media from CCBE1 and ADAMTS3 
transfected cells were mixed with [35S]-labeled VEGF-C-WT or VEGF-C-MUT conditioned media (CCBE1:VEGF-C:ADAMTS3 ratio 1:5:5). For 
wild-type VEGF-C, small amounts of ADAMTS3 and/or CCBE1 result in appreciable generation of mature VEGF-C, whereas the same amounts 
of CCBE1 and ADAMTS3 have little or no effect on VEGF-C-MUT (compare red boxed mature VEGF-C). The signal ratio of mature VEGF-C to 
pro-VEGF-C is shown in red
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of either the unidirectional intraluminal valves and/or of the 
fibrous molecular links between the outer surface of the lym-
phatic wall and the surrounding tissue fibers.
Lymphoscintigraphic evidences for the limbs of the twin 
brother and father show a significantly reduced foot-to-ingui-
nal dye distribution after mild exercise, suggesting again that 
the lower limbs lymphatic trunks did not benefit of the ex-
trinsic propulsive contribution. However, at least at this stage 
of development, no sign of clinical lymphedema has been 
observed yet. Indeed, in line with the incomplete penetrance 
showed by the Fastrè et al (Fastré et al., 2018), the proband's 
mother carrying the c.148-3_148-2delCA variation had no 
lymphoscintigraphic alterations or signs of lymphedema.
Given the role of the novel variant in our family, we per-
formed an in vitro study with the aim to explain the pheno-
type of the carriers of the VEGF-C Ser65Arg variant. Our 
findings showed that the proteolytic processing of the mu-
tant is decreased in comparison with wild-type VEGF-C. 
ADAMTS3 interacts directly with the N-terminal propep-
tide of VEGF-C (VEGF-C-NT), and the Ser65Arg mutation 
alters the ability of VEGF-C to interact with ADAMTS3, 
thus reducing the processing and therefore the activation of 
VEGF-C. Together, our findings support the role of the mu-
tant protein in lymphedema, since both the twin brother and 
the father have reduced lymphatic drainage, although not yet 
showing symptoms of the disease.
Given this, the interpretation of the role of these two 
variants in the proband remains to be clarified. Milroy-like 
disease has been described as transferred by variant in auto-
somal dominant state. However, we cannot exclude that they 
both have a pathogenic effect. Thus, based on our clinical 
and experimental findings, we propose that the Ser65Arg 
mutation affects VEGF-C processing and thus may contrib-
ute to lymphedema. The arguments in favor of the role of 
the Ser65arg variant are: (a) it is a rare variant; (b) in silico 
prediction is supportive of a pathogenic role for the variant; 
(c) in vitro study confirmed a role in the reduction of activity 
of VEGF-C; (d) the variant co-segregate with a subclinical 
phenotype in the family. Instead, the variant c.148-3_148-
2delCA has been shown elsewhere to be causative of 
lymphedema due to exon 2 and 3 skipping with the conse-
quent deletion of 135 of the 419 amino acids of the protein. 
Moreover, we can hypothesize that the overt phenotype in 
the proband is due to the additive inactivation of VEGF-C 
due to the hypomorphic VEGF-C missense variant in a hap-
loinsufficiency setting. This is not new in lymphedema; in 
particular, the work of Ghalamkarpour et al. described that 
VEGFR-3 lymphedema, usually associated with a dom-
inant transmission, can be caused also by an hypomorphic 
homozygous VEGFR-3 mutation (p.Ala855Thr) that im-
pact the functioning of the receptor to a lesser extent than 
a dominantly inherited VEGFR-3 mutation (Ghalamkarpour 
et  al.,  2009). In addition, also in VEGF-C animals model, 
a residual activity of an hypomorphic vegfc allele has been 
documented by Vivien et al., which showed in zebrafish that 
hypomorphic vegfc allele in association with a loss of func-
tion of vegfd could still retain few lymphatic vessels on the 
bulbous arteriosus while this was not possible in a double 
mutant line (Vivien et al., 2019). In conclusion, the present 
data may provide an important contribution to unveil the 
etiology of Milroy-like lymphedema and improve the possi-
ble inheritance pathway associated to VEGF-C. Indeed, this 
study suggests that polymorphism on the other allele might 
modify the illness presentation explaining the huge variation 
of penetrance observed in families with VEGF-C mutations.
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